Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 143

Results For "Pharmaceutical"

3129 News Found

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery
Digitisation | January 11, 2024

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb


GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
News | January 10, 2024

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway


Caplin Group announces strategic investment of Rs. 700 crore in TN
News | January 09, 2024

Caplin Group announces strategic investment of Rs. 700 crore in TN

This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited


Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr
News | January 08, 2024

Arco Lab acquires an additional 25% stake in Neviton at Rs. 9.22 Cr

Arco Lab now holds a 50% stake in Neviton


Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore
News | January 08, 2024

Mandaviya inaugurates CDSCO Sub Zonal Office and Central Drug Testing Laboratory in Indore

Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh


Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
News | January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.


Supriya Lifesciences received GMP certification from ANVISA Brazil
News | January 06, 2024

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA


Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Drug Approval | January 04, 2024

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US


Strides Pharma Science to invest in AMP-6, AMP-8
News | January 03, 2024

Strides Pharma Science to invest in AMP-6, AMP-8

AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka